Bruton's tyrosine kinase inhibitors: approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and B cell malignancies.

Article Details

Citation

Copy to clipboard

Lou Y, Owens TD, Kuglstatter A, Kondru RK, Goldstein DM

Bruton's tyrosine kinase inhibitors: approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and B cell malignancies.

J Med Chem. 2012 May 24;55(10):4539-50. doi: 10.1021/jm300035p. Epub 2012 Mar 21.

PubMed ID

22394077 [ View in PubMed

]

Abstract

Not Available

DrugBank Data that Cites this Article

Binding Properties

Drug	Target	Property	Measurement	pH	Temperature (°C)
Dasatinib	Tyrosine-protein kinase BTK	IC 50 (nM)	5	N/A	N/A	Details